ArticleBrain circulation
Intravenous thrombolysis for acute ischemic stroke: From alteplase to tenecteplase.
Article in Brain circulation. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Alteplase versus tenecteplase in acute ischemic stroke with large vessel occlusion: a systematic review and meta-analysis.European journal of clinical pharmacology · 2026Pooled it
- Trial
- Trial
- Stroke-heart syndrome outcomes in pre-existing vs. new-onset dementia: a report from a global federated research network.Journal of thrombosis and thrombolysis · 2026Article
- Zinc dyshomeostasis, mitochondrial dysfunction, and their pathological cycle in ischemic stroke pathophysiology: Mechanisms and potential therapeutic targets.Redox biology · 2026Review
- Article
- Optimizing Early Antithrombotic Therapy Within 24 Hours of Intravenous Thrombolysis in Acute Ischemic Stroke.CNS drugs · 2026Review
- Safety and Efficacy of Early Aspirin Administration After Intravenous Thrombolysis for Acute Ischemic Stroke (TREND-IVT): Rationale and Design of a Multicenter, Randomized, Placebo-Controlled Clinical Trial.Journal of the American Heart Association · 2026Article
- Revisiting Incomplete Tissue-Level Reperfusion Following Successful Thrombectomy for Acute Ischemic Stroke.Annals of neurology · 2026Review
- Article
- Rationale and Study Design to Assess the Efficacy and Safety of Minocycline in Patients with Moderate to Severe Acute Ischaemic Stroke (EMPHASIS).Stroke and vascular neurology · 2025Article
- Review
- Early Risk Prediction Model for Stroke-Heart Syndrome Following Endovascular Therapy.Aging and disease · 2025Article
- A matters arising: discussion on urokinase dosing and individualized treatment strategies in the TRUST trial.BMC medicine · 2025Article
- Clinical outcomes of endovascular therapy in acute basilar artery occlusion with low pc-ASPECTS : Outcomes in ABAO with low pc-ASPECTS.Journal of neurology · 2025Article
- Updates in Intravenous Thrombolysis Treatment for Acute Ischemic Stroke in Asian Populations.Aging and disease · 2025Review
- Mitigating Early Phosphatidylserine Exposure in a Tmem30a-Dependent Way Ameliorates Neuronal Damages After Ischemic Stroke.MedComm · 2025Article
- Endothelial Cells and the Blood-Brain Barrier: Critical Determinants of Ineffective Reperfusion in Stroke.The European journal of neuroscience · 2025Review
- Prediction of outcomes following intravenous thrombolysis in patients with acute ischemic stroke using serum UCH-L1, S100β, and NSE: a multicenter prospective cohort study employing machine learning methods.Therapeutic advances in neurological disorders · 2025Article
- Molecular targets of neuroplasticity in ischemic stroke: insights from GEO database, single-cell analysis and immune infiltration analysis.Frontiers in aging neuroscience · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stroke is one of the primary causes of morbidity and death worldwide. While intravenous (IV) thrombolysis with alteplase has been widely proven to be beneficial for acute ischemic stroke patients, it still has many limitations. Tenecteplase, a revised version of alteplase, is a potential alternative IV thrombolytic agent that has benefits over alteplase. The aim of this mini-review is to summarize the advancements in IV thrombolysis for severe ischemic stroke, specifically the development and transition from alteplase to tenecteplase.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.